Taikang Life Insurance
24
304M
21
0.86
6
0.12
6
- Areas of investment
Summary
Taikang Life Insurance appeared to be the Corporate Investor, which was created in 1996. The leading representative office of defined Corporate Investor is situated in the Beijing. The fund was located in Asia if to be more exact in China.
For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight EasyHome, Innovent Biologics, Womai. Among the most popular fund investment industries, there are Biotechnology, Biopharma. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups.
Besides them, we counted 2 critical employees of this fund in our database.
The fund is generally included in 2-6 deals every year. The top amount of exits for fund were in 2019. Considering the real fund results, this Corporate Investor is 9 percentage points more often commits exit comparing to other organizations. This Taikang Life Insurance works on 14 percentage points more the average amount of lead investments comparing to the other organizations. The common things for fund are deals in the range of more than 100 millions dollars. The average startup value when the investment from Taikang Life Insurance is more than 1 billion dollars. The high activity for fund was in 2019.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Taikang Life Insurance, startups are often financed by Lilly Asia Ventures, F-Prime Capital, Temasek Holdings. The meaningful sponsors for the fund in investment in the same round are Temasek Holdings, Lilly Asia Ventures, Legend Capital. In the next rounds fund is usually obtained by Temasek Holdings, Hillhouse Capital Group, Lilly Asia Ventures.
Investments analytics
Analytics
- Total investments
- 24
- Lead investments
- 6
- Exits
- 6
- Rounds per year
- 0.86
- Follow on index
- 0.12
- Investments by industry
- Biotechnology (10)
- Biopharma (6)
- Health Care (6)
- E-Commerce (5)
- Pharmaceutical (5) Show 32 more
- Investments by region
-
- China (21)
- United States (1)
- Peak activity year
- 2021
- Number of Unicorns
- 4
- Number of Decacorns
- 4
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 10
- Avg. valuation at time of investment
- 507M
- Group Appearance index
- 0.96
- Avg. company exit year
- 4
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| EOC Pharma Group | 07 Nov 2017 | Biotechnology, Health Care, Pharmaceutical, Biopharma | Early Stage Venture | 32M | Shanghai, China |
| STARTDT | 01 Dec 2022 | Late Stage Venture | 15M | ||
| Turing Chain | 30 Jul 2022 | Software, SaaS, EdTech, Blockchain, E-Signature | Seed | 500K | Taipei, Taiwan |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.